Today

Agents

Chat

Arena

Discover

More

App

Chugai says FDA grants priority review for Roche’s Enspryng in MOGAD - RHHBY News | Rallies

Chugai says FDA grants priority review for Roche’s Enspryng in MOGAD

RHHBY•2026-09-10

European filing validated

EMA validated the EU filing for adult MOGAD; European Commission decision expected in Q3 2027.

FDA grants priority review for Enspryng in MOGAD

Chugai reported Roche secured FDA Priority Review for Enspryng (satralizumab) in MOGAD for adult, adolescent patients.

US decision deadline set for Jan. 10, 2027.

Related News

Rackspace plans Blackwell-powered sovereign AI pods for regulated enterprises, governments

RXT•2026-09-10

SEALSQ expands Quantum Highway with ninth hub in Chicago via EeroQ investment

LAES•2026-09-10

American Eagle shares slide as flat margin outlook, weak core brand weigh

Sources

D

Chugai says FDA grants priority review for Roche’s Enspryng in MOGAD

Docs

AEO

•

2026-09-10

Metals-Copper sets record on tight non-US supply, oil holds firm

XLB•2026-09-10

Vietnam's Grab drivers call for two-day app boycott over falling earnings

GRAB•2026-09-10